Aerovate Therapeutics (AVTE) Competitors $9.50 -0.64 (-6.31%) As of 04/30/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVTE vs. CMPS, TKNO, ALLO, TRDA, TSHA, HRTX, ATYR, ARCT, ATAI, and PVLAShould you be buying Aerovate Therapeutics stock or one of its competitors? The main competitors of Aerovate Therapeutics include COMPASS Pathways (CMPS), Alpha Teknova (TKNO), Allogene Therapeutics (ALLO), Entrada Therapeutics (TRDA), Taysha Gene Therapies (TSHA), Heron Therapeutics (HRTX), Atyr PHARMA (ATYR), Arcturus Therapeutics (ARCT), Atai Life Sciences (ATAI), and Palvella Therapeutics (PVLA). These companies are all part of the "pharmaceutical products" industry. Aerovate Therapeutics vs. COMPASS Pathways Alpha Teknova Allogene Therapeutics Entrada Therapeutics Taysha Gene Therapies Heron Therapeutics Atyr PHARMA Arcturus Therapeutics Atai Life Sciences Palvella Therapeutics Aerovate Therapeutics (NASDAQ:AVTE) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk. Does the media prefer AVTE or CMPS? In the previous week, Aerovate Therapeutics had 1 more articles in the media than COMPASS Pathways. MarketBeat recorded 9 mentions for Aerovate Therapeutics and 8 mentions for COMPASS Pathways. COMPASS Pathways' average media sentiment score of 1.31 beat Aerovate Therapeutics' score of 0.92 indicating that COMPASS Pathways is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aerovate Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive COMPASS Pathways 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is AVTE or CMPS more profitable? COMPASS Pathways' return on equity of -63.85% beat Aerovate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aerovate TherapeuticsN/A -90.19% -77.47% COMPASS Pathways N/A -63.85%-51.97% Which has preferable earnings & valuation, AVTE or CMPS? Aerovate Therapeutics is trading at a lower price-to-earnings ratio than COMPASS Pathways, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAerovate TherapeuticsN/AN/A-$75.52M-$1.70-5.96COMPASS PathwaysN/AN/A-$118.46M-$2.30-1.76 Do analysts prefer AVTE or CMPS? Aerovate Therapeutics presently has a consensus target price of $2.25, indicating a potential downside of 77.81%. COMPASS Pathways has a consensus target price of $20.20, indicating a potential upside of 399.26%. Given COMPASS Pathways' stronger consensus rating and higher possible upside, analysts plainly believe COMPASS Pathways is more favorable than Aerovate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00COMPASS Pathways 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, AVTE or CMPS? Aerovate Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.34, indicating that its share price is 134% more volatile than the S&P 500. Do insiders & institutionals believe in AVTE or CMPS? 46.2% of COMPASS Pathways shares are owned by institutional investors. 24.9% of Aerovate Therapeutics shares are owned by insiders. Comparatively, 4.3% of COMPASS Pathways shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer AVTE or CMPS? COMPASS Pathways received 47 more outperform votes than Aerovate Therapeutics when rated by MarketBeat users. Likewise, 81.48% of users gave COMPASS Pathways an outperform vote while only 54.29% of users gave Aerovate Therapeutics an outperform vote. CompanyUnderperformOutperformAerovate TherapeuticsOutperform Votes1954.29% Underperform Votes1645.71% COMPASS PathwaysOutperform Votes6681.48% Underperform Votes1518.52% SummaryCOMPASS Pathways beats Aerovate Therapeutics on 11 of the 15 factors compared between the two stocks. Get Aerovate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTE vs. The Competition Export to ExcelMetricAerovate TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$293.91M$6.75B$5.51B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-3.397.3222.5518.49Price / SalesN/A239.19394.97102.66Price / CashN/A65.8538.1834.62Price / Book2.566.436.694.25Net Income-$75.52M$143.21M$3.22B$248.31M7 Day Performance272.79%1.24%1.11%1.12%1 Month Performance303.98%6.09%3.59%3.68%1 Year Performance-51.34%-3.34%15.65%5.19% Aerovate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTEAerovate Therapeutics0.4024 of 5 stars$9.50-6.3%$2.25-76.3%-49.3%$275.36MN/A-3.1820Earnings ReportOptions VolumeNews CoverageHigh Trading VolumeCMPSCOMPASS Pathways2.4281 of 5 stars$3.38+8.0%$20.20+497.6%-53.6%$313.24MN/A-1.54120Upcoming EarningsNews CoveragePositive NewsTKNOAlpha Teknova1.8859 of 5 stars$5.78+0.3%$8.50+47.1%+274.7%$308.87M$37.75M-7.81240News CoverageALLOAllogene Therapeutics3.4326 of 5 stars$1.42-2.1%$9.29+554.1%-39.1%$308.52M$22,000.00-0.91310Positive NewsTRDAEntrada Therapeutics2.9967 of 5 stars$7.95-2.2%$25.67+222.9%-23.0%$298.88M$210.78M5.00110Upcoming EarningsNews CoverageHigh Trading VolumeTSHATaysha Gene Therapies1.9624 of 5 stars$1.45+16.9%$6.63+356.9%-20.2%$297.33M$8.33M2.30180Analyst ForecastNews CoverageHRTXHeron Therapeutics3.7204 of 5 stars$1.93+4.9%$5.67+193.6%+4.3%$294.00M$144.29M-10.72300Upcoming EarningsNews CoverageATYRAtyr PHARMA2.5624 of 5 stars$3.28+5.8%$18.60+467.1%N/A$291.46M$235,000.00-3.4953Short Interest ↑News CoverageARCTArcturus Therapeutics2.9843 of 5 stars$11.00+4.5%$59.20+438.2%-49.9%$285.57M$138.39M-4.95180News CoveragePositive NewsATAIAtai Life Sciences2.6868 of 5 stars$1.42-3.4%$10.50+639.4%-24.2%$283.69M$308,000.00-1.7580Positive NewsPVLAPalvella Therapeutics3.4144 of 5 stars$25.45+4.5%$44.43+74.6%N/A$280.43M$42.81M-2.10N/AAnalyst ForecastPositive NewsHigh Trading Volume Related Companies and Tools Related Companies COMPASS Pathways Competitors Alpha Teknova Competitors Allogene Therapeutics Competitors Entrada Therapeutics Competitors Taysha Gene Therapies Competitors Heron Therapeutics Competitors Atyr PHARMA Competitors Arcturus Therapeutics Competitors Atai Life Sciences Competitors Palvella Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVTE) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AVTE Stock Free AVTE Stock Alerts